Oral anticoagulants are commonly used drugs in patients with CKD and patients with ESKD
to treat atrial fibrillation to reduce stroke and systemic embolism. Some of these drugs are …

Background There is a lack of clear benefit and a potential risk of bleeding with direct oral
anticoagulant (DOAC) use in chronic kidney disease (CKD) and dialysis patients with atrial …

Patients with chronic kidney disease (CKD) are predisposed to heart rhythm disorders,
including atrial fibrillation (AF)/atrial flutter, supraventricular tachycardias, ventricular …

Background: Both atrial fibrillation and venous thromboembolism (VTE) are highly prevalent
among patients with chronic kidney disease (CKD). Until recently, warfarin was the most …

Objective: To evaluate how treatment with DOACs for VTE affects thrombosis and bleeding
outcomes compared to warfarin in CKD and dialysis patients. Data Sources: A literature …

Increasing use of direct oral anticoagulants (DOAC s) has made management of non‐
valvular atrial fibrillation and venous thromboembolism easier in most patients. But the …

Atrial fibrillation (AF) and renal insufficiency often coexist and are increasingly prevalent with
advancing age. Both the risk of thromboembolic events and bleeding propensity are higher …

Atrial fibrillation (AF) is the most frequent arrhythmia in common clinical practice and its
prevalence is markedly increased among patients with chronic kidney disease (CKD). The …

A growing number of patients with an indication for stroke prevention in atrial fibrillation have
kidney‐, age‐, or weight‐related alterations in pharmacokinetics that affect dosing of direct …

With the growing integration of non–vitamin K antagonist oral anticoagulants (NOACs) into
clinical practice, questions have arisen regarding their use in special populations, including …